Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
valuation ratios | |
|---|---|
| pe ratio | -1.09 |
| peg ratio | -0.01 |
| price to book ratio | -7.71 |
| price to sales ratio | 0.00 |
| enterprise value multiple | -1.13 |
| price fair value | -7.71 |
profitability ratios | |
|---|---|
| gross profit margin | 0.0% |
| operating profit margin | 0.0% |
| pretax profit margin | 0.0% |
| net profit margin | 0.0% |
| return on assets | -470.48% |
| return on equity | 581.58% |
| return on capital employed | 674.27% |
liquidity ratio | |
|---|---|
| current ratio | 0.60 |
| quick ratio | 0.60 |
| cash ratio | 0.35 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 153.32 |
| cash conversion cycle | -153.32 |
| receivables turnover | 0.00 |
| payables turnover | 2.38 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 1.07 |
| debt equity ratio | -1.60 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 2.66 |
| interest coverage | -11.48 |
| cash flow to debt ratio | -2.40 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.95 |
| cash per share | 0.22 |
| operating cash flow per share | -0.95 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -2.40 |
| short term coverage ratios | -2.40 |
| capital expenditure coverage ratio | 0.00 |
Frequently Asked Questions
Chromocell Therapeutics Corporation (CHRO) published its most recent earnings results on 13-11-2024.
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Chromocell Therapeutics Corporation (AMEX:CHRO)'s trailing twelve months ROE is 581.58%.
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Chromocell Therapeutics Corporation (CHRO) currently has a ROA of -470.48%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
CHRO reported a profit margin of 0.0% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
Apple's current ratio, which measures its ability to pay short-term obligations, was 0.60 in the most recent quarter. The quick ratio stood at 0.60, with a Debt/Eq ratio of -1.60.